Analysts Expect Soleno Therapeutics, Inc. (NASDAQ:SLNO) to Announce -$0.08 EPS

Wall Street analysts predict that Soleno Therapeutics, Inc. (NASDAQ:SLNO) will announce ($0.08) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have provided estimates for Soleno Therapeutics’ earnings. Soleno Therapeutics reported earnings of ($0.16) per share in the same quarter last year, which would indicate a positive year over year growth rate of 50%. The business is expected to issue its next quarterly earnings report on Monday, August 9th.

On average, analysts expect that Soleno Therapeutics will report full year earnings of ($0.32) per share for the current financial year. For the next financial year, analysts expect that the business will report earnings of ($0.27) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that follow Soleno Therapeutics.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings data on Wednesday, May 5th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.03).

Separately, Zacks Investment Research upgraded Soleno Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday.

A number of large investors have recently made changes to their positions in the business. Warberg Asset Management LLC acquired a new position in shares of Soleno Therapeutics in the first quarter worth $38,000. Clayton Partners LLC acquired a new position in shares of Soleno Therapeutics in the first quarter worth $126,000. Barclays PLC increased its stake in shares of Soleno Therapeutics by 159.0% in the first quarter. Barclays PLC now owns 49,804 shares of the company’s stock worth $63,000 after acquiring an additional 30,576 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Soleno Therapeutics by 15.0% in the first quarter. Geode Capital Management LLC now owns 827,746 shares of the company’s stock worth $1,042,000 after acquiring an additional 108,234 shares during the last quarter. Finally, UBS Group AG increased its stake in shares of Soleno Therapeutics by 269.6% in the first quarter. UBS Group AG now owns 36,976 shares of the company’s stock worth $47,000 after acquiring an additional 26,971 shares during the last quarter. 40.97% of the stock is currently owned by institutional investors.

SLNO traded down $0.01 during trading on Thursday, reaching $0.98. The stock had a trading volume of 2,149 shares, compared to its average volume of 1,130,791. The stock has a market cap of $78.51 million, a price-to-earnings ratio of -2.36 and a beta of 0.43. Soleno Therapeutics has a 1-year low of $0.91 and a 1-year high of $3.36. The stock has a 50 day simple moving average of $1.06.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program.

Featured Story: What is the QQQ ETF?

Get a free copy of the Zacks research report on Soleno Therapeutics (SLNO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.